Brendan O'Leary, PhD

Brendan O'Leary, PhD, has a diverse work experience in the biotech and investment banking sectors. From 2023, they have served as the Chief Executive Officer of Autobahn Labs, a biotech accelerator backed by Samsara BioCapital and Evotec. Prior to this, Brendan worked at Bowen, a growth tech investment bank, where they held the positions of Head of Life Sciences and Senior Advisor from 2022 to 2023. Brendan also co-founded Delta TpX, Inc. in 2019 and played a key role in the company until 2023. Additionally, Brendan has experience in life sciences consulting as the Managing Partner of OLFIT Life Sciences Consulting, which they held from 2021 to 2022.

Brendan's work history also includes co-founding and serving as the Managing Director of AllosteRx Capital, an investment firm, from 2018 to 2021. Furthermore, they served as the General Partner and Managing Director at Prism Venture Partners from 2003 to 2020, where they played a pivotal role in the firm's operations and investment strategies. Brendan's earlier experience includes their appointment as the Executive Vice Chancellor for Innovation and Business Development at UMass Medical School from 2014 to 2017. Overall, Brendan O'Leary's work experience showcases their expertise in biotech entrepreneurship, investment banking, and business strategy.

Brendan O'Leary, PhD completed their education in a chronological order. Brendan first attended Middlebury College from 1990 to 1994, where they earned a Bachelor of Arts (B.A.) degree in Chemistry and Economics. Following this, they pursued their passion for chemistry and enrolled at the Massachusetts Institute of Technology where they obtained their Doctor of Philosophy (Ph.D.) in Organic Chemistry between 1994 and 1999. During their doctoral studies, they also worked as a Visiting Student and Research Assistant at Scripps Research from 1996 to 1999, further refining their expertise in the field of Organic Chemistry.